Publications by authors named "M Brengues"
The impact of curative radiotherapy mainly depends on the total dose delivered to the tumor. However, despite recent technological advances, the dose delivered to surrounding healthy tissues may reduce the therapeutic ratio of many radiation treatments. In the same population treated at one center with the same technique, individual radiosensitivity clearly exists, particularly in terms of late side effects that are, in principle, non-reversible.
View Article and Find Full Text PDFThe genetic background of each person might affect the severity of radiotherapy (RT)-induced normal tissue toxicity. The aim of study was to evaluate the influence of TGFB1 C-509T and Leu10Pro, XRCC1 Arg280His and XRCC3 Thr241Met polymorphisms as well as the level of radiation-induced CD8 T-lymphocyte apoptosis (RILA) on adverse effects of RT for prostate cancer (PCa). The study included 88 patients with localized or locally advanced PCa who were treated with RT.
View Article and Find Full Text PDFBackground: Circadian rhythm impacts broad biological processes, including response to cancer treatment. Evidence conflicts on whether treatment time affects risk of radiotherapy side-effects, likely because of differing time analyses and target tissues. We previously showed interactive effects of time and genotypes of circadian genes on late toxicity after breast radiotherapy and aimed to validate those results in a multi-centre cohort.
View Article and Find Full Text PDFArticle Synopsis
- - Personalized cancer treatments have become essential in oncology, leading to better outcomes but also increasing the focus on long-term side effects for survivors, with 5-10% facing severe late toxicity from radiotherapy.
- - The identification of patients at risk for severe side effects before treatment can allow adjustments in their care to enhance their quality of life, for which various tests and biomarkers have been created over the years.
- - Among these tests, the Radiation-Induced Lymphocyte Apoptosis (RILA) assay has been the only one prospectively validated on a large scale and shows promise in predicting late radiation-induced toxicity across multiple cancer types, aiding decision-making in precision radiation oncology.
The place of personalized treatments is highly increasing in medical and radiation oncology. During the last decades, a huge number of assays have been developed to predict responses of normal tissues and tumours. These tests have not yet been included into daily clinical practice but the recent developments of radiation oncology are paving the way of personalized strategies including the risk of tumour recurrence and normal tissue reactions.
View Article and Find Full Text PDF